Table 2.

Effects of rifaximin (R) administration on symptoms in patients with diverticular disease

First author (year, ref)	Pts (n)	Treatment (type)	Duration (months)	Reduction in symptoms(%)	P
Papi (1992, 64)	217	R (400 mg daily) + glucomannan (2 g daily) vs glucomannan	12	63.9 vs 47.6	< 0.001
Papi (1995, 65)	168	R (400 mg daily) + glucomannan (2 g daily) vs placebo +glucomannan	12	68.9 vs 38.5	< 0.001
Latella (2003, 66)	968	R (400 mg daily) + glucomannan (4 g daily) vs glucomannan	12	56.5 vs 29.2	< 0.001